Nkarta (NKTX) Gets a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Leerink Partners Remains a Buy on Century Therapeutics (IPSC)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Hosted on MSN10mon
Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday
One patients showed normal B cells after a year. Leerink Partners analyst Daina Graybosch says the results prove the benefit for NKX019, which the company is also testing in patients with lupus ...